J
Jazz Pharmaceuticals plc (JAZZ)
NMS – Real vaqt narxi. Valyuta: USD
230.02
+3.82 (1.69%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
232.00
+1.98 (0.86%)
Bozordan keyin: Jun 26, 2026, 5:01 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
230.02
+3.82 (1.69%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
232.00
+1.98 (0.86%)
Bozordan keyin: Jun 26, 2026, 5:01 PM EDT
Jazz Pharmaceuticals plc Qo'shma Shtatlar, Evropa va xalqaro miqyosda farmatsevtik mahsulotlarni aniqlaydi, ishlab chiqadi va tijoratlashtiradi. Kompaniya narkolepsiya bilan bog'liq katapleksiya yoki haddan tashqari kunduzgi uyquchanlikni (EDS) va idiopatik giperinsomniyani (IH) davolash uchun Xywavni; Lennox-Gastaut sindromi (LGS), Dravet sindromi (DS) yoki tuberoz skleroz kompleksi (TSC) bilan bog'liq tirishmalarni davolash uchun Epidiolexni; o'tkir limfoblastik leykemiyani yoki limfoblastik limfomani davolash uchun Rylazeni; o'tkir limfoblastik leykemiyani va limfoblastik limfomani davolash uchun Enrylazeni; platina asosidagi kimyoterapiya paytida yoki undan keyin kasallikning rivojlanishi bilan kechadigan metastatik mayda hujayrali o'pka saratonini davolash uchun Zepzelcani; HER2-musbat o't yo'llari saratonini davolash uchun Ziiherani; H3 K27M mutatsiyasiga ega bo'lgan diffuz midline gliomasini davolash uchun Modeyso va og'ir veno-okkluziv kasallikni davolash uchun Defitelioni taklif etadi. Kompaniya, shuningdek, HER2-musbat gastroezofageal adenokarsinoma (GEA) va o't yo'llari saratonini (BTC) davolash uchun 3-bosqich sinovida Zanidatamabni; H3 K27M-mutatsiyali diffuz gliomani davolash uchun Dordaviprone va yangi tashxis qo'yilgan, terapiya bilan bog'liq o'tkir miyeloid leykemiyani davolash uchun Vyxeosni ishlab chiqmoqda. Bundan tashqari, kompaniya ko'krak bezi saratonining neoad'yuvant va adjuvant davolash uchun Zanidatamabni; yuqori xavfli MDS, yuqori xavfli AML bilan yangi tashxis qo'yilgan davolanmagan bemorlar va genomika bo'yicha stratifikatsiyalangan yuqori xavfli AMLni davolash uchun Vyxeosni va 2-bosqich klinik sinovlarida bo'lgan feoxromotsitoma va paragangliomani davolash uchun JZP3507ni ishlab chiqmoqda. Bundan tashqari, u Raf va Ras mutant o'smalarini davolash uchun JZP815ni; qattiq o'smalarda IFN INDUKIN molekulasi uchun JZP898ni va 1-bosqich klinik sinovlarida bo'lgan absans epilepsiyani davolash uchun JZP047ni ishlab chiqmoqda. Kompaniya Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc. va AbCellera Biologics Inc. bilan litsenziyalash va hamkorlik shartnomalariga ega. Jazz Pharmaceuticals plc 2003 yilda tashkil etilgan va uning bosh qarorgohi Dublin, Irlandiyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development |
| Mr. Bruce C. Cozadd | Co-Founder & Chairman |
| Mr. John D. Bluth | Head of Investor Relations |
| Mr. Philip L. Johnson | Executive VP & CFO |
| Ms. Heidi Manna | Executive VP & Chief People Officer |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer |
| Ms. Renee D. Gala | President, CEO & Director |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-08 | DEF 14A | jazz-20260605.htm |
| 2026-05-29 | PRE 14A | jazz-20260529.htm |
| 2026-05-29 | 8-K | jazz-20260525.htm |
| 2026-05-05 | 8-K | jazz-20260505.htm |
| 2026-05-05 | 10-Q | jazz-20260331.htm |
| 2026-04-24 | 10-K/A | jazz-20251231.htm |
| 2026-02-24 | 8-K | jazz-20260224.htm |
| 2026-01-12 | 8-K | d61589d8k.htm |
| 2025-11-17 | 8-K | d827060d8k.htm |
| 2025-11-05 | 8-K | jazz-20251105.htm |